Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;20(11):7529-7546.
doi: 10.1002/alz.14231. Epub 2024 Oct 1.

Examination of plasma biomarkers of amyloid, tau, neurodegeneration, and neuroinflammation in former elite American football players

Affiliations

Examination of plasma biomarkers of amyloid, tau, neurodegeneration, and neuroinflammation in former elite American football players

Annalise E Miner et al. Alzheimers Dement. 2024 Nov.

Abstract

Introduction: Blood-based biomarkers offer a promising approach for the detection of neuropathologies from repetitive head impacts (RHI). We evaluated plasma biomarkers of amyloid, tau, neurodegeneration, and inflammation in former football players.

Methods: The sample included 180 former football players and 60 asymptomatic, unexposed male participants (aged 45-74). Plasma assays were conducted for beta-amyloid (Aβ) 40, Aβ42, hyper-phosphorylated tau (p-tau) 181+231, total tau (t-tau), neurofilament light (NfL), glial fibrillary acidic protein (GFAP), interleukin-6 (IL-6), Aβ42/p-tau181 and Aβ42/Aβ40 ratios. We evaluated their ability to differentiate the groups and associations with RHI proxies and traumatic encephalopathy syndrome (TES).

Results: P-tau181 and p-tau231(padj = 0.016) were higher and Aβ42/p-tau181 was lower(padj = 0.004) in football players compared to controls. Discrimination accuracy for p-tau was modest (area under the curve [AUC] = 0.742). Effects were not attributable to AD-related pathology. Younger age of first exposure (AFE) correlated with higher NfL (padj = 0.03) and GFAP (padj = 0.033). Plasma GFAP was higher in TES-chronic traumatic encephalopathy (TES-CTE) Possible/Probable (padj = 0.008).

Discussion: Plasma p-tau181 and p-tau231, GFAP, and NfL may offer some usefulness for the characterization of RHI-related neuropathologies.

Highlights: Former football players had higher plasma p-tau181 and p-tau231 and lower Aβ42/ptau-181 compared to asymptomatic, unexposed men. Younger age of first exposure was associated with increased plasma NfL and GFAP in older but not younger participants. Plasma GFAP was higher in participants with TES-CTE possible/probable compared to TES-CTE no/suggestive.

Keywords: National Football League; chronic traumatic encephalopathy; college football; concussion; football; head trauma; neurodegenerative disease; plasma biomarkers; repetitive head impacts; subconcussion; traumatic brain injury; traumatic encephalopathy syndrome.

PubMed Disclaimer

Conflict of interest statement

L.J.B. is Editor‐in‐chief of the Journal of Neuro‐Ophthalmology. C.B. receives research support from the Ultimate Fighting Championship, Top Rank promotions, and Haymon Boxing. H.Z. has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co‐founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). K.B. has served as a consultant and on advisory boards for AC Immune, Acumen, ALZPath, AriBio, BioArctic, Biogen, Eisai, Lilly, and Moleac Pte. Ltd, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served on data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials, and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co‐founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. E.P. has served as consultant, on scientific advisory boards, or on data monitoring committees for Eli Lilly, Avanir, Acadia, Roche, Regeneron, and ALPHA‐Cognition. EMR is a compensated scientific advisor for Alkahest, Alzheon, Aural Analytics, Denali, Green Valley, Retromer Therapeutics, and Vaxxinity, and a co‐founder of ALZPath. W.B.B. provides expert witness testimony in legal cases involving concussion and CTE. R.C.C. is a Senior Advisor to the NFL Head Neck & Spine Committee; Vice President, National Operating Committee on Standards for Athletic Equipment; and Chair, Scientific Advisory Committee, Co‐Founder, and Medical Director, Concussion Legacy Foundation. He is a member of the Medical Science Committee for the National Collegiate Athletic Association Student‐Athlete Concussion Injury Litigation, and he receives royalties for published books from Houghton Mifflin Harcourt. D.W.D. reports the following competing interests: Consulting: AEON, Amgen, Clexio, Cerecin, Cooltech, Ctrl M, Allergan, Alder, Biohaven, GSK, Linpharma, Lundbeck, Promius, Eli Lilly, eNeura, Novartis, Impel, Satsuma, Theranica, WL Gore, Nocira, XoC, Zosano, Upjohn (Division of Pfizer), Pieris, Praxis, Revance, Equinox. Honoraria: Clinical Care Solutions, CME Outfitters, Curry Rockefeller Group, DeepBench, Global Access Meetings, KLJ Associates, Academy for Continued Healthcare Learning, Majallin LLC, Medlogix Communications, MJH Lifesciences, Miller Medical Communications, Southern Headache Society (MAHEC), WebMD Health/Medscape, Wolters Kluwer, Oxford University Press, Cambridge University Press. Research Support: Department of Defense, National Institutes of Health, Henry Jackson Foundation, Sperling Foundation, American Migraine Foundation, Patient Centered Outcomes Research Institute (PCORI). Stock Options/Shareholder/Patents/Board of Directors: Ctrl M (options), Aural analytics (options), ExSano (options), Palion (options), Healint (Options), Theranica (Options), Second Opinion/Mobile Health (Options), Epien (Options/Board), Nocira (options), Matterhorn (Shares/Board), Ontologics (Shares/Board), King‐Devick Technologies (Options/Board), Precon Health (Options/Board). Patent 17189376.1‐1466:vTitle: Botulinum Toxin Dosage Regimen for Chronic Migraine Prophylaxis. D.I.K. received royalties from Springer/Demos Publishing for a textbook on brain injury; serves as an expert witness in legal cases involving brain injury and concussion; receives a stipend from Encompass Health as program medical director for brain injury and chair of the annual Neurorehabilitation conference; and has received honoraria for a keynote address for the HealthSouth Annual Medical Directors Meeting. J.L.C. has provided consultation to Acadia, Actinogen, Acumen, AlphaCognition, Aprinoia, AriBio, Artery, Biogen, BioVie, Bristol‐Myers Squib, Cassava, Cerecin, Diadem, EIP Pharma, Eisai, GemVax, Genentech, GAP Innovations, Janssen, Jocasta, Karuna, Lighthouse, Lilly, Lundbeck, LSP/EQT, Merck, NervGen, Novo Nordisk, Oligomerix, Optoceutics, Ono, Otsuka, PRODEO, Prothena, ReMYND, Roche, Sage Therapeutics, Signant Health, Simcere, Suven, SynapseBio, TrueBinding, Vaxxinity, and Wren pharmaceutical, assessment, and investment companies. He owns the copyright of the Neuropsychiatric Inventory. E.M.R. is a compensated scientific advisor for Alkahest, Alzheon, Aural Analytics, Denali, Green Valley, Retromer Therapeutics, and Vaxxinity, and a co‐founder of ALZPath. R.A.S. is a member of the Board of Directors of King‐Devick Technologies, Inc. (Chicago, IL, USA), and he receives royalties for published neuropsychological tests from Psychological Assessment Resources, Inc. (Lutz, FL, USA), and consulting fees from Eisai. M.L.A. receives royalties from Oxford University Press Inc and has received honorarium from the Michael J Fox Foundation for services unrelated to this study. He also reports research support from Life Molecular Imaging Inc and Rainwater Charitable Foundation Inc. A.E.M., J.R.G., Y.T., C.H.A., N.J.A., C.E.G., B.M., J.N.P., S.J.B., J.W., J.M., S.A., and M.E.S. have nothing to report. Author disclosures are available in the Supporting Information.

Figures

FIGURE 1
FIGURE 1
Estimated marginal means plot—pT181, pT231. ANCOVA compared concentrations of plasma biomarkers in football players and asymptomatic UE participants. Above figure shows the differences in estimated marginal means between football players and asymptomatic UE exposure groups for plasma p‐Tau181, p‐Tau231, and the Aβ42/p‐Tau181 ratio. All models adjusted for age, race, BMI, rFSRP, and total AUDIT score. Error bars at 95% CI. (a) p‐Tau181. (b) p‐Tau231. (c). Aβ42/p‐Tau181. ANCOVA, analysis of covariance; AUDIT, alcohol use disorders identification test; BMI, body mass index; CI, confidence interval; p‐tau, hyper‐phosphorylated tau; rFSRP, revised Framingham Stroke Risk Profile; UE, unexposed
FIGURE 2
FIGURE 2
Plasma biomarker concentrations. Concentrations of plasma biomarkers after log‐transformation by ln() (if applicable) between football players (RHI) and asymptomatic UE participants (No RHI) exposure groups shown as boxplots. Individual data points are shown. Stars denote statistically significant results. Plasma biomarker concentrations are shown on the y‐axis. pg/dL, picograms per deciliter; pg/mL, picograms per milliliter, RHI, repetitive head impacts; UE, unexposed.
FIGURE 3
FIGURE 3
Plasma biomarker ROC curve analysis. ROC curve analysis of plasma biomarkers differentiating capability between football exposure groups (former players vs. asymptomatic UE participants). Binomial regression models were performed. Adjusted analysis included age, race, BMI, rFSRP and total AUDIT score. AUDIT, alcohol use disorders identification test; BMI, body mass index; rFSRP, revised Framingham Stroke Risk Profile; ROC, receiver operating characteristic; UE, unexposed.
FIGURE 4
FIGURE 4
GFAP concentrations and TES‐CTE certainty. Concentrations of plasma GFAP after log‐transformation by ln() between TES‐CTE possible/probable (left) and TES‐No/TES‐CTE Suggestive (right). Individual data points are shown. Plasma GFAP concentrations are shown on the y‐axis. GFAP, glial fibrillary acidic protein; pg/dL, picograms per deciliter; TES‐CTE, traumatic encephalopathy syndrome‐chronic traumatic encephalopathy.
FIGURE 5
FIGURE 5
Association between plasma NfL, GFAP, and AFE. Results of regression models for starting age of football on both plasma NfL (left, blue; NfL Δ R= 0.033, B = −0.011, padj = 0.03) and GFAP (right, maroon; GFAP Δ R= 0.022, B = −0.008, padj = 0.033). These partial regression plots show the results with covariates taken into account and include a regression line with 95% CI. Covariates include age, race, BMI, rFSRP, total AUDIT score and total years of football play. AFE, age of first exposure; AUDIT, alcohol use disorders identification test; BMI, body mass index; CI, confidence interval; GFAP, glial fibrillary acidic protein; NfL, neurofilament light; rFSRP, revised Framingham Stroke Risk Profile.

References

    1. Cherry JD, Tripodis Y, Alvarez VE, et al. Microglial neuroinflammation contributes to tau accumulation in chronic traumatic encephalopathy. Acta Neuropathol Commun. 2016;4(1):112. - PMC - PubMed
    1. Saltiel N, Tripodis Y, Menzin T, et al. Relative contributions of mixed pathologies to cognitive and functional symptoms in brain donors exposed to repetitive head impacts. Ann Neurol. 2024;95(2):314‐324. - PMC - PubMed
    1. Daneshvar DH, Nair ES, Baucom ZH, et al. Leveraging football accelerometer data to quantify associations between repetitive head impacts and chronic traumatic encephalopathy in males. Nat Commun. 2023;14(1):3470. - PMC - PubMed
    1. Alosco ML, Stein TD, Tripodis Y, et al. Association of white matter rarefaction, arteriolosclerosis, and tau with dementia in chronic traumatic encephalopathy. JAMA Neurol. 2019;76(11):1298‐1308. - PMC - PubMed
    1. McKee AC, Stein TD, Nowinski CJ, et al. The spectrum of disease in chronic traumatic encephalopathy. Brain. 2013;136(Pt 1):43‐64. - PMC - PubMed

Grants and funding

LinkOut - more resources